Status: Recruiting
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ryan Gentzler, MDUpdated: Apr 8, 2026Locations: 3
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+26]
Prior treatment with KRAS G12C tyrosine kinase inhibitor. [+8]